Biomarkers for personalized medicine in GI cancers
- PMID: 26054566
- DOI: 10.1016/j.mam.2015.06.002
Biomarkers for personalized medicine in GI cancers
Abstract
Gastrointestinal malignancies are a major health care challenge due to the high incidence and overall poor outcome. A biomarker is a molecular characteristic of a tumor that may be utilized in the initial risk assessment and the subsequent management of the patient. This review focuses on the most pertinent prognostic and predictive biomarkers used in the clinical management of gastric, pancreas, and colon cancer. The available assays, limitations and clinical use for each biomarker are reviewed. The clinical trials evaluating novel biomarkers in GI cancers are discussed.
Keywords: Biomarkers; Colorectal cancer; Gastric cancer; Gastrointestinal malignancy; Pancreatic cancer; Personalized medicine.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening.Gastroenterol Clin North Am. 2016 Sep;45(3):529-42. doi: 10.1016/j.gtc.2016.04.009. Gastroenterol Clin North Am. 2016. PMID: 27546847 Review.
-
The current state of molecular profiling in gastrointestinal malignancies.Biol Direct. 2022 Jun 6;17(1):15. doi: 10.1186/s13062-022-00322-0. Biol Direct. 2022. PMID: 35668531 Free PMC article. Review.
-
microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.Adv Exp Med Biol. 2015;888:5-15. doi: 10.1007/978-3-319-22671-2_2. Adv Exp Med Biol. 2015. PMID: 26663176 Review.
-
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.Eur J Cancer. 2017 Nov;86:305-317. doi: 10.1016/j.ejca.2017.09.021. Epub 2017 Oct 21. Eur J Cancer. 2017. PMID: 29065378 Review.
-
Targeting dynamics of subclones of GI, liver and pancreatic cancers.Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):773-6. doi: 10.1080/17474124.2016.1179578. Epub 2016 May 3. Expert Rev Gastroenterol Hepatol. 2016. PMID: 27143511 No abstract available.
Cited by
-
Identification of the RP11-21C4.1/SVEP1 gene pair associated with FAT2 mutations as a potential biomarker in gastric cancer.Bioengineered. 2021 Dec;12(1):4361-4373. doi: 10.1080/21655979.2021.1953211. Bioengineered. 2021. PMID: 34308747 Free PMC article.
-
Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer.Cell Death Dis. 2019 Sep 20;10(10):697. doi: 10.1038/s41419-019-1907-4. Cell Death Dis. 2019. PMID: 31541076 Free PMC article.
-
Elevated limb-bud and heart development (LBH) expression indicates poor prognosis and promotes gastric cancer cell proliferation and invasion via upregulating Integrin/FAK/Akt pathway.PeerJ. 2019 May 6;7:e6885. doi: 10.7717/peerj.6885. eCollection 2019. PeerJ. 2019. PMID: 31119084 Free PMC article.
-
Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer.Tumour Biol. 2016 Apr;37(4):4439-44. doi: 10.1007/s13277-015-4288-z. Epub 2015 Oct 25. Tumour Biol. 2016. PMID: 26499948
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
